Cargando…
Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects
Mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants can compromise the effectiveness of therapeutic antibodies. Most clinical-stage therapeutic antibodies target the spike receptor binding domain (RBD), but variants often have multiple mutations in...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754225/ https://www.ncbi.nlm.nih.gov/pubmed/34668774 http://dx.doi.org/10.1128/JVI.01110-21 |
_version_ | 1784632227203645440 |
---|---|
author | Lusvarghi, Sabrina Wang, Wei Herrup, Rachel Neerukonda, Sabari Nath Vassell, Russell Bentley, Lisa Eakin, Ann E. Erlandson, Karl J. Weiss, Carol D. |
author_facet | Lusvarghi, Sabrina Wang, Wei Herrup, Rachel Neerukonda, Sabari Nath Vassell, Russell Bentley, Lisa Eakin, Ann E. Erlandson, Karl J. Weiss, Carol D. |
author_sort | Lusvarghi, Sabrina |
collection | PubMed |
description | Mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants can compromise the effectiveness of therapeutic antibodies. Most clinical-stage therapeutic antibodies target the spike receptor binding domain (RBD), but variants often have multiple mutations in several spike regions. To help predict antibody potency against emerging variants, we evaluated 25 clinical-stage therapeutic antibodies for neutralization activity against 60 pseudoviruses bearing spikes with single or multiple substitutions in several spike domains, including the full set of substitutions in B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), B.1.429 (epsilon), B.1.526 (iota), A.23.1, and R.1 variants. We found that 14 of 15 single antibodies were vulnerable to at least one RBD substitution, but most combination and polyclonal therapeutic antibodies remained potent. Key substitutions in variants with multiple spike substitutions predicted resistance, but the degree of resistance could be modified in unpredictable ways by other spike substitutions that may reside outside the RBD. These findings highlight the importance of assessing antibody potency in the context of all substitutions in a variant and show that epistatic interactions in spike can modify virus susceptibility to therapeutic antibodies. IMPORTANCE Therapeutic antibodies are effective in preventing severe disease from SARS-CoV-2 infection (COVID-19), but their effectiveness may be reduced by virus variants with mutations affecting the spike protein. To help predict resistance to therapeutic antibodies in emerging variants, we profiled resistance patterns of 25 antibody products in late stages of clinical development against a large panel of variants that include single and multiple substitutions found in the spike protein. We found that the presence of a key substitution in variants with multiple spike substitutions can predict resistance against a variant but that other substitutions can affect the degree of resistance in unpredictable ways. These findings highlight complex interactions among substitutions in the spike protein affecting virus neutralization and, potentially, virus entry into cells. |
format | Online Article Text |
id | pubmed-8754225 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-87542252022-01-24 Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects Lusvarghi, Sabrina Wang, Wei Herrup, Rachel Neerukonda, Sabari Nath Vassell, Russell Bentley, Lisa Eakin, Ann E. Erlandson, Karl J. Weiss, Carol D. J Virol Vaccines and Antiviral Agents Mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants can compromise the effectiveness of therapeutic antibodies. Most clinical-stage therapeutic antibodies target the spike receptor binding domain (RBD), but variants often have multiple mutations in several spike regions. To help predict antibody potency against emerging variants, we evaluated 25 clinical-stage therapeutic antibodies for neutralization activity against 60 pseudoviruses bearing spikes with single or multiple substitutions in several spike domains, including the full set of substitutions in B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), B.1.429 (epsilon), B.1.526 (iota), A.23.1, and R.1 variants. We found that 14 of 15 single antibodies were vulnerable to at least one RBD substitution, but most combination and polyclonal therapeutic antibodies remained potent. Key substitutions in variants with multiple spike substitutions predicted resistance, but the degree of resistance could be modified in unpredictable ways by other spike substitutions that may reside outside the RBD. These findings highlight the importance of assessing antibody potency in the context of all substitutions in a variant and show that epistatic interactions in spike can modify virus susceptibility to therapeutic antibodies. IMPORTANCE Therapeutic antibodies are effective in preventing severe disease from SARS-CoV-2 infection (COVID-19), but their effectiveness may be reduced by virus variants with mutations affecting the spike protein. To help predict resistance to therapeutic antibodies in emerging variants, we profiled resistance patterns of 25 antibody products in late stages of clinical development against a large panel of variants that include single and multiple substitutions found in the spike protein. We found that the presence of a key substitution in variants with multiple spike substitutions can predict resistance against a variant but that other substitutions can affect the degree of resistance in unpredictable ways. These findings highlight complex interactions among substitutions in the spike protein affecting virus neutralization and, potentially, virus entry into cells. American Society for Microbiology 2022-01-12 /pmc/articles/PMC8754225/ /pubmed/34668774 http://dx.doi.org/10.1128/JVI.01110-21 Text en This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply. https://doi.org/10.1128/ASMCopyrightv2This article is made available via the PMC Open Access Subset for unrestricted noncommercial re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Vaccines and Antiviral Agents Lusvarghi, Sabrina Wang, Wei Herrup, Rachel Neerukonda, Sabari Nath Vassell, Russell Bentley, Lisa Eakin, Ann E. Erlandson, Karl J. Weiss, Carol D. Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects |
title | Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects |
title_full | Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects |
title_fullStr | Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects |
title_full_unstemmed | Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects |
title_short | Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects |
title_sort | key substitutions in the spike protein of sars-cov-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects |
topic | Vaccines and Antiviral Agents |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754225/ https://www.ncbi.nlm.nih.gov/pubmed/34668774 http://dx.doi.org/10.1128/JVI.01110-21 |
work_keys_str_mv | AT lusvarghisabrina keysubstitutionsinthespikeproteinofsarscov2variantscanpredictresistancetomonoclonalantibodiesbutothersubstitutionscanmodifytheeffects AT wangwei keysubstitutionsinthespikeproteinofsarscov2variantscanpredictresistancetomonoclonalantibodiesbutothersubstitutionscanmodifytheeffects AT herruprachel keysubstitutionsinthespikeproteinofsarscov2variantscanpredictresistancetomonoclonalantibodiesbutothersubstitutionscanmodifytheeffects AT neerukondasabarinath keysubstitutionsinthespikeproteinofsarscov2variantscanpredictresistancetomonoclonalantibodiesbutothersubstitutionscanmodifytheeffects AT vassellrussell keysubstitutionsinthespikeproteinofsarscov2variantscanpredictresistancetomonoclonalantibodiesbutothersubstitutionscanmodifytheeffects AT bentleylisa keysubstitutionsinthespikeproteinofsarscov2variantscanpredictresistancetomonoclonalantibodiesbutothersubstitutionscanmodifytheeffects AT eakinanne keysubstitutionsinthespikeproteinofsarscov2variantscanpredictresistancetomonoclonalantibodiesbutothersubstitutionscanmodifytheeffects AT erlandsonkarlj keysubstitutionsinthespikeproteinofsarscov2variantscanpredictresistancetomonoclonalantibodiesbutothersubstitutionscanmodifytheeffects AT weisscarold keysubstitutionsinthespikeproteinofsarscov2variantscanpredictresistancetomonoclonalantibodiesbutothersubstitutionscanmodifytheeffects |